S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
S&P 500   4,320.06
DOW   33,963.84
QQQ   356.31
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
LON:AGL

ANGLE (AGL) Competitors

GBX 15.51
-0.24 (-1.52%)
(As of 01:41 PM ET)
Compare
Today's Range
15.51
▼
15.84
50-Day Range
11
▼
19
52-Week Range
10.65
▼
70
Volume
90,241 shs
Average Volume
1.87 million shs
Market Capitalization
£40.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 120
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines

AGL vs. LLAI, PRM, YGEN, VRCI, ABDX, GENI, GDR, DXRX, MED, and VLG

Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include LungLife AI (LLAI), Proteome Sciences (PRM), Yourgene Health (YGEN), Verici Dx (VRCI), Abingdon Health (ABDX), GENinCode (GENI), genedrive (GDR), Diaceutics (DXRX), Intelligent Ultrasound Group plc (MED.L) (MED), and Venture Life Group (VLG). These companies are all part of the "medical" sector.

ANGLE vs.

LungLife AI (LON:LLAI) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.

ANGLE received 180 more outperform votes than LungLife AI when rated by MarketBeat users.

CompanyUnderperformOutperform
LungLife AIN/AN/A
ANGLEOutperform Votes
180
62.07%
Underperform Votes
110
37.93%

ANGLE's return on equity of -44.84% beat LungLife AI's return on equity.

Company Net Margins Return on Equity Return on Assets
LungLife AIN/A -44.84% -25.93%
ANGLE N/A -69.68%-38.07%

LungLife AI has higher earnings, but lower revenue than ANGLE. LungLife AI is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LungLife AI£98.57K245.68-£5.94M-£0.22-431.82
ANGLE£1.82M22.21-£22.28M-£0.08-193.88

42.3% of LungLife AI shares are owned by institutional investors. Comparatively, 32.4% of ANGLE shares are owned by institutional investors. 62.6% of LungLife AI shares are owned by insiders. Comparatively, 10.8% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, ANGLE had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for LungLife AI. LungLife AI's average media sentiment score of 0.67 beat ANGLE's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
LungLife AI Neutral
ANGLE Positive

ANGLE has a consensus target price of GBX 120, indicating a potential upside of 666.19%. Given LungLife AI's higher probable upside, analysts plainly believe ANGLE is more favorable than LungLife AI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LungLife AI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

LungLife AI has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.

Summary

ANGLE beats LungLife AI on 9 of the 15 factors compared between the two stocks.


Get ANGLE News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGL vs. The Competition

Export to Excel
MetricANGLEDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£40.42M£25.32M£4.31B£1.33B
Dividend YieldN/A8.13%5.83%13.49%
P/E Ratio-193.88612.6690.851,513.17
Price / Sales22.213,305.602,938.4051,217.05
Price / Cash5.8017.8921.3332.82
Price / Book1.293.003.912.51
Net Income-£22.28M-£28.48M£120.18M£194.31M
7 Day Performance5.15%-3.21%111.10%5.55%
1 Month Performance21.65%-4.60%114.32%6.95%
1 Year Performance-75.77%-27.57%130.51%24.05%

ANGLE Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLAI
LungLife AI
0 of 5 stars		GBX 103.30
-0.2%		N/AN/A£26.33M£98,566.00-516.5015
PRM
Proteome Sciences
0 of 5 stars		GBX 6.05
-3.7%		N/A+36.0%£17.86M£7.75M418.0024Gap Down
YGEN
Yourgene Health
0 of 5 stars		GBX 0.52
flat		N/A-89.0%£16.43M£29.67M-51.50253
VRCI
Verici Dx
0 of 5 stars		GBX 8.75
flat		N/A-41.6%£14.90MN/A-145.8315
ABDX
Abingdon Health
0 of 5 stars		GBX 10.75
-2.3%		N/A+48.3%£13.09M£2.24M-179.1774
GENI
GENinCode
0 of 5 stars		GBX 11.50
flat		N/A-38.3%£11.02M£1.43M-191.6734
GDR
genedrive
0 of 5 stars		GBX 10.65
-3.2%		N/A-16.0%£10.87M£49,000.00-213.0040
DXRX
Diaceutics
0 of 5 stars		GBX 104
flat		GBX 150
+44.2%		+14.7%£87.85M£19.50M10,400.00151
MED
Intelligent Ultrasound Group plc (MED.L)
0 of 5 stars		N/AN/AN/A£39.06M£5.28M-7.6345Gap Down
VLG
Venture Life Group
0 of 5 stars		GBX 31
flat		N/A+21.7%£39.22M£43.98M2,075.00153Gap Down

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (LON:AGL) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -